Cell therapy reporting preferences will take effect in July 2022 and will be used to determine how forms come due.
Reporting Preferences
Do Not Perform
- This option should be selected if the site does not perform cellular therapies (this excludes DLIs)
Perform Do Not Report
- This option should be selected if the center performs this infusion type, but does not report the data to CIBMTR.
Research (RES)
- All cellular therapies performed at the site are submitted to CIBMTR
- This includes commercial products, and investigator studies and clinical trials
Regulatory (RGL)
- Commercially available cell therapy products only are submitted to CIBMTR
- Examples: Kymriah®, Yescarta®, TecartusTM, Breyanzi®, Abecma®
If you would like to change the cellular therapy reporting preference for your center or have questions about which reporting preference has been chosen, please submit a ticket via CIBMTR Center Support.
Last modified:
May 25, 2022